No Data
No Data
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160
European Equities Traded in the US as American Depositary Receipts Move Slightly Higher in Thursday Trading
Ascendis Pharma Ticks Higher Amid Report It Cancelled From Upcoming Conference
MBX Bio Drops Despite Bullish Views on Street
Septerna, Hypoparathyroidism Drug Developer, Files for $100M IPO
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug